This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Sildenafil Treatment of Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction

Adam Keller Ashton and Richard G. Bennett

Published: March 31, 1999

Article Abstract

Letter to the Editor

Sir: Serotonin reuptake inhibiting antidepressants (SRIs) are reported to cause decreases in sexual desire, arousal, and orgasm. Augmentation strategies proposed to reduce SRI-induced sexual dysfunction include cyproheptadine, yohimbine, amantadine, stimulants, buspirone, bupropion, and Ginkgo biloba. Drug holiday also has been forwarded as a treatment option. Spontaneous remission of SRI-induced sexual dysfunction is uncommon: reports suggest that this occurs in from 5.8% of patients within 6 months to 9.8% of patients followed up to 38 months on continuing treatment.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 60

Quick Links: Depression (MDD) , Sexual Dysfunction


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...